JP2010532989A5 - - Google Patents

Download PDF

Info

Publication number
JP2010532989A5
JP2010532989A5 JP2010515648A JP2010515648A JP2010532989A5 JP 2010532989 A5 JP2010532989 A5 JP 2010532989A5 JP 2010515648 A JP2010515648 A JP 2010515648A JP 2010515648 A JP2010515648 A JP 2010515648A JP 2010532989 A5 JP2010532989 A5 JP 2010532989A5
Authority
JP
Japan
Prior art keywords
seq
homologous
amino acid
coordinates
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010515648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010532989A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2008/052786 external-priority patent/WO2009007934A2/en
Publication of JP2010532989A publication Critical patent/JP2010532989A/ja
Publication of JP2010532989A5 publication Critical patent/JP2010532989A5/ja
Pending legal-status Critical Current

Links

JP2010515648A 2007-07-10 2008-07-10 神経変性疾患におけるcd44スプライスバリアント Pending JP2010532989A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92970607P 2007-07-10 2007-07-10
PCT/IB2008/052786 WO2009007934A2 (en) 2007-07-10 2008-07-10 Cd44 splice variants in neurodegenerative diseases

Publications (2)

Publication Number Publication Date
JP2010532989A JP2010532989A (ja) 2010-10-21
JP2010532989A5 true JP2010532989A5 (enExample) 2011-08-25

Family

ID=40229192

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010515648A Pending JP2010532989A (ja) 2007-07-10 2008-07-10 神経変性疾患におけるcd44スプライスバリアント

Country Status (15)

Country Link
US (2) US9018180B2 (enExample)
EP (1) EP2167692B1 (enExample)
JP (1) JP2010532989A (enExample)
KR (1) KR20100044793A (enExample)
CN (1) CN101821407B (enExample)
AU (1) AU2008273713B2 (enExample)
BR (1) BRPI0814685A2 (enExample)
CA (1) CA2692861A1 (enExample)
EA (1) EA201070108A1 (enExample)
ES (1) ES2423182T3 (enExample)
IL (1) IL203130A (enExample)
MX (1) MX2010000236A (enExample)
NZ (1) NZ582390A (enExample)
WO (1) WO2009007934A2 (enExample)
ZA (1) ZA201000083B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0821227A2 (pt) 2007-12-19 2015-06-16 Cancer Rec Tech Ltd Composto, composição farmacêutica, método para preparar a mesma, uso de um composto, método para tratar uma doença ou distúrbio, para inibir função de raf e para inibir proliferação celular, inibir progressão do ciclo celular, promover apoptose, ou uma combinação de um ou mais dos mesmos
EP2531502B1 (en) 2010-02-01 2014-04-02 Cancer Research Technology Limited 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
JP5960793B2 (ja) 2011-03-24 2016-08-02 ニューリム ファーマシューティカルズ(1991)リミテッド 神経保護ペプチド
US9399779B2 (en) * 2011-06-08 2016-07-26 The Corporation Of Mercer University Alternative splicing constructs and methods of use
CN104277092B (zh) * 2013-07-12 2017-10-31 天津医科大学 用于预防和/或治疗老年性痴呆的β片层阻断肽
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
US10400009B2 (en) 2014-09-04 2019-09-03 Tianjin Medical University β-sheet breaker peptide used for preventing and/or treating alzheimer's disease
CN107815438A (zh) * 2017-08-02 2018-03-20 清华大学 重组细胞、筛选l型钙通道调节剂的方法、试剂在制备药物中的用途和药物组合物
MX2023013420A (es) 2021-05-11 2023-12-06 Neurim Pharmaceuticals 1991 Ltd Metodo para diagnosticar y tratar sujetos que tienen polimorfismos de un solo nucleotido en el cromosoma 2, locus 2:107,510,000-107,540,000.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990299A (en) * 1995-08-14 1999-11-23 Icn Pharmaceuticals, Inc. Control of CD44 gene expression for therapeutic use
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6150162A (en) 1998-12-17 2000-11-21 Isis Pharmaceuticals Inc. Antisense modulation of CD44 expression
IL133647A0 (en) * 1999-06-08 2001-04-30 Yissum Res Dev Co Novel cd44 variant
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
EP1309726B2 (en) 2000-03-30 2018-10-03 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
RU2322500C2 (ru) * 2000-12-01 2008-04-20 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. Малые молекулы рнк, опосредующие интерференцию рнк
CA2439630A1 (en) 2001-03-23 2002-10-03 Agy Therapeutics Use of biomolecular targets in the treatment and visualization of brain tumors
CN1511040A (zh) 2001-05-25 2004-07-07 ����˹���ѷ��ѧ 作为多种治疗模式基础的蛋白质的选择性剪接形式
US7833779B2 (en) * 2001-07-25 2010-11-16 Jivan Biologies Inc. Methods and systems for polynucleotide detection
EP1670943B1 (en) * 2003-09-30 2013-11-13 Evotec International GmbH Diagnostic and therapeutic use of a sulfotransferase for alzheimer's disease
ATE495269T1 (de) * 2005-06-16 2011-01-15 Evotec Neurosciences Gmbh Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen

Similar Documents

Publication Publication Date Title
JP2010532989A5 (enExample)
JP2008249727A5 (enExample)
JP6219824B2 (ja) びまん性大細胞型b細胞性リンパ腫(dlbcl)患者における抗−cd20療法に対する応答の予測
CA2818887A1 (en) Diagnostic and/or screening agents and uses therefor
JP2014533949A5 (enExample)
JP2012115275A5 (enExample)
JP2011528903A5 (enExample)
JP2009519703A5 (enExample)
JP2005522999A5 (enExample)
JP2011519275A5 (enExample)
WO2010015618A1 (en) Method for determining a predisposition to basal cell carcinoma and for screening treatments thereof
JP6531312B2 (ja) Bcr−abl阻害剤耐性関連変異の検出方法及びこれを用いたbcr−abl阻害剤耐性を予測するためのデータ取得方法
JP2011517937A5 (enExample)
CA2263895A1 (en) Therapeutic and diagnostic applications of perlecan domain i splice variants
JP2009515524A5 (enExample)
CN105296659A (zh) 一种与缺血性脑卒中相关的基因标记物
JP2009539370A5 (enExample)
KR20110004918A (ko) 비만 유전자 증폭용 프라이머 세트, 그것을 포함하는 비만 유전자 증폭용 시약 및 그 용도
KR101820616B1 (ko) 개체가 결장직장암을 앓을 확률을 시험관내에서 측정하는 방법 및 키트
SG184704A1 (en) Use of clec1b for the determination of cardiovascular and thrombotic risk
KR101657051B1 (ko) 만성폐쇄성폐질환 진단용 마커 조성물
CN105543400B (zh) I型糖尿病的分子标志物
CN107043811A (zh) Cfap20基因在骨质疏松症诊断中的应用
CA2525179A1 (en) A gene equation to diagnose rheumatoid arthritis
CN107164507A (zh) 绝经后妇女原发性骨质疏松症的诊断工具